- Home
- HAFN vs PTGX Comparison
HAFN vs PTGX Comparison
Compare HAFN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- PTGX
- Stock Information
- Founded
- HAFN 2012
- PTGX 2006
- Country
- HAFN Bermuda
- PTGX United States
- Employees
- HAFN N/A
- PTGX N/A
- Industry
- HAFN
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HAFN
- PTGX Health Care
- Exchange
- HAFN Nasdaq
- PTGX Nasdaq
- Market Cap
- HAFN 2.8B
- PTGX 2.7B
- IPO Year
- HAFN N/A
- PTGX 2016
- Fundamental
- Price
- HAFN $5.22
- PTGX $40.69
- Analyst Decision
- HAFN Strong Buy
- PTGX Strong Buy
- Analyst Count
- HAFN 2
- PTGX 8
- Target Price
- HAFN $8.25
- PTGX $54.63
- AVG Volume (30 Days)
- HAFN 3.3M
- PTGX 817.5K
- Earning Date
- HAFN 11-27-2024
- PTGX 11-07-2024
- Dividend Yield
- HAFN 29.04%
- PTGX N/A
- EPS Growth
- HAFN N/A
- PTGX N/A
- EPS
- HAFN 1.69
- PTGX 2.68
- Revenue
- HAFN $3,039,225,000.00
- PTGX $323,795,000.00
- Revenue This Year
- HAFN N/A
- PTGX $441.08
- Revenue Next Year
- HAFN N/A
- PTGX N/A
- P/E Ratio
- HAFN $3.09
- PTGX $15.16
- Revenue Growth
- HAFN 15.24
- PTGX 125.73
- 52 Week Low
- HAFN $5.07
- PTGX $20.71
- 52 Week High
- HAFN $8.99
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- PTGX 42.76
- Support Level
- HAFN N/A
- PTGX $39.60
- Resistance Level
- HAFN N/A
- PTGX $41.97
- Average True Range (ATR)
- HAFN 0.00
- PTGX 1.80
- MACD
- HAFN 0.00
- PTGX -0.04
- Stochastic Oscillator
- HAFN 0.00
- PTGX 18.17
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.